Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that...

Full description

Bibliographic Details
Main Authors: Diego J. Maselli, Holly Keyt, Marcos I. Restrepo
Format: Article
Language:English
Published: MDPI AG 2017-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/18/5/1062
id doaj-3ae1a36e2b6f452cbab6ed349ab05f89
record_format Article
spelling doaj-3ae1a36e2b6f452cbab6ed349ab05f892020-11-24T20:52:19ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-05-01185106210.3390/ijms18051062ijms18051062Inhaled Antibiotic Therapy in Chronic Respiratory DiseasesDiego J. Maselli0Holly Keyt1Marcos I. Restrepo2Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX 78229, USADivision of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX 78229, USADivision of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX 78229, USAThe management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.http://www.mdpi.com/1422-0067/18/5/1062aerosolscystic fibrosisbronchiectasisnontuberculous mycobacteria
collection DOAJ
language English
format Article
sources DOAJ
author Diego J. Maselli
Holly Keyt
Marcos I. Restrepo
spellingShingle Diego J. Maselli
Holly Keyt
Marcos I. Restrepo
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
International Journal of Molecular Sciences
aerosols
cystic fibrosis
bronchiectasis
nontuberculous mycobacteria
author_facet Diego J. Maselli
Holly Keyt
Marcos I. Restrepo
author_sort Diego J. Maselli
title Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
title_short Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
title_full Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
title_fullStr Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
title_full_unstemmed Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
title_sort inhaled antibiotic therapy in chronic respiratory diseases
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2017-05-01
description The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.
topic aerosols
cystic fibrosis
bronchiectasis
nontuberculous mycobacteria
url http://www.mdpi.com/1422-0067/18/5/1062
work_keys_str_mv AT diegojmaselli inhaledantibiotictherapyinchronicrespiratorydiseases
AT hollykeyt inhaledantibiotictherapyinchronicrespiratorydiseases
AT marcosirestrepo inhaledantibiotictherapyinchronicrespiratorydiseases
_version_ 1716800013260029952